Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics

Read More

Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation

Read More

Ligand Reports Third Quarter 2018 Financial Results

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range